ECM
BMRN icon

ETrade Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

ETrade Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,890
Closed -$973K – 890
2020
Q2 		$973K Buy
7,890
+2,702
+52% +$269K 0.02% 358
2020
Q1 		$438K Buy
+5,188
New +$447K 0.01% 500
2019
Q4 		– Sell
-4,030
Closed -$272K – 793
2019
Q3 		$272K Sell
4,030
-1,736
-30% -$134K 0.01% 703
2019
Q2 		$494K Sell
5,766
-1,528
-21% -$131K 0.01% 567
2019
Q1 		$648K Sell
7,294
-939
-11% -$87K 0.02% 450
2018
Q4 		$701K Sell
8,233
-677
-8% -$64.4K 0.02% 401
2018
Q3 		$864K Buy
8,910
+774
+10% +$77.3K 0.02% 405
2018
Q2 		$766K Buy
8,136
+591
+8% +$51.8K 0.02% 418
2018
Q1 		$612K Buy
7,545
+653
+9% +$56K 0.02% 459
2017
Q4 		$615K Buy
6,892
+1,473
+27% +$128K 0.02% 454
2017
Q3 		$504K Buy
5,419
+891
+20% +$78.7K 0.02% 467
2017
Q2 		$411K Buy
4,528
+300
+7% +$27.3K 0.02% 495
2017
Q1 		$371K Buy
4,228
+882
+26% +$78.5K 0.02% 486
2016
Q4 		$277K Sell
3,346
-568
-15% -$48.8K 0.01% 488
2016
Q3 		$362K Buy
3,914
+859
+28% +$80.9K 0.02% 424
2016
Q2 		$238K Buy
+3,055
New +$260K 0.01% 439

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ETrade Capital Management's BMRN Position: Q3 2020 in Review

ETrade Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 7,890 shares — an estimated $973K sold.

ETrade Capital Management first reported a position in BMRN in Q2 2016 and held it in 16 quarters. The position peaked at $973K in Q2 2020. 497 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

  • ETrade Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • ETrade Capital Management sold 7,890 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $973K.
  • ETrade Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2016 and held it in 16 quarters.
  • ETrade Capital Management's BioMarin Pharmaceuticals position peaked at $973K in Q2 2020.
  • 497 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.